Bioo Therapeutics, a division of Bioo Scientific, was launched to leverage Bioo Scientific’s proprietary drug delivery vehicles and extensive experience in antibody and small molecule research to use as a basis to develop therapeutic agents to combat cancer and other diseases.
Bioo Therapeutics flagship drug delivery technology is a patent pending antibody conjugation technology which delivers small RNA drugs into specifically targeted cells or tissues.
The scientists at Bioo Scientific have made significant strides in developing and using antibody-based agents for the directed delivery of short interfering RNAs by improving the loading capacity of antibody drug carriers and demonstrating their ability to successfully deliver small RNAs into tumors generated from cells expressing the cell surface target.
Drugs or toxins can be attached to monoclonal antibodies which target a specific cell type forming monoclonal antibody conjugates. These monoclonal antibody conjugates are used as homing devices to deliver these substances directly into targeted cells. This patent pending technology can revolutionize the delivery of siRNA and other RNAi agents, as well as, other more traditional drugs.
"Bioo Therapeutics is actively seeking to partner with pharmaceutical companies or venture capitalists to make possible the therapeutic potential of this technology. This effort will advance targeted drug delivery which is vitally important for the development of new cures and treatments of cancer," said Lance Ford, VP of Research and Business Development for Bioo Scientific. This research is being supported by funding in part through grants from the National Science Foundation (NSF), the National Institute of Allergy and Infectious Disease (NIAID) and clients.